ABAT
4-aminobutyrate aminotransferase, mitochondrial
As of the edition of 20 October 2026, ABAT (4-aminobutyrate aminotransferase, mitochondrial, UniProt P80404) has 2 drugs tested at it and 5 companies on the list, 1 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P80404
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Disease areas
- Nervous system; Mental health; Chemically induced; Inherited and neonatal; Cancer; Digestive system; Heart and blood vessels; Immune system
- Registered trials of its drugs
- 22
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vigabatrin | Marketed | Phase 4 | none listed |
| Cpp-115 free base | Went quiet | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 3 |
| Undetermined | 1 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Orphelia Pharma | Route B |
| Pyros Pharmaceuticals | Route B |
| Angelini Pharma | Route A |
The other 2 companies at ABAT
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at ABAT, ranked, with the facts behind eachRequest access. Nothing is shown until you do.